| Year |
Citation |
Score |
| 2023 |
Kanapka L, Ivanova A. Fully order restricted multi-arm multi-stage clinical trial design. Statistics in Medicine. 42: 3050-3066. PMID 37190881 DOI: 10.1002/sim.9767 |
0.306 |
|
| 2023 |
Saha PT, Fine JP, Ivanova A. CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome. Statistics in Medicine. PMID 37012897 DOI: 10.1002/sim.9729 |
0.358 |
|
| 2021 |
Saha PT, Fine JP, Ivanova A. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM. Statistics in Medicine. PMID 33588519 DOI: 10.1002/sim.8892 |
0.316 |
|
| 2020 |
Li X, Ivanova A, Tian H, Lim P, Liu K. Continual reassessment method with regularization in phase I clinical trials. Journal of Biopharmaceutical Statistics. 1-15. PMID 32926652 DOI: 10.1080/10543406.2020.1818251 |
0.384 |
|
| 2020 |
Chang Y, Song T, Monaco J, Ivanova A. Futility stopping in clinical trials, optimality and practical considerations. Journal of Biopharmaceutical Statistics. 1-10. PMID 32926648 DOI: 10.1080/10543406.2020.1818253 |
0.38 |
|
| 2020 |
Liu Y, Lyu J, Bell Burdett K, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, et al. Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib. Molecular Cancer Therapeutics. PMID 32747417 DOI: 10.1158/1535-7163.Mct-20-0249 |
0.329 |
|
| 2019 |
Karachaliou GS, Ayvali F, Collichio FA, Lee CB, Ivanova A, Ollila DW, Moschos SJ. Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience. Oncology. 1-5. PMID 31794964 DOI: 10.1159/000504578 |
0.305 |
|
| 2019 |
Wiener LE, Ivanova A, Li S, Silverman RK, Koch GG. Randomization-based analysis of covariance for inference in the sequential parallel comparison design. Journal of Biopharmaceutical Statistics. 1-18. PMID 31304861 DOI: 10.1080/10543406.2019.1633660 |
0.364 |
|
| 2019 |
Joshi N, Fine J, Chu R, Ivanova A. Estimating the subgroup and testing for treatment effect in a post-hoc analysis of aclinical trial with a biomarker. Journal of Biopharmaceutical Statistics. 1-11. PMID 31269870 DOI: 10.1080/10543406.2019.1633655 |
0.319 |
|
| 2019 |
Xue X, Foster MC, Ivanova A. Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups. Journal of Biopharmaceutical Statistics. 1-10. PMID 31251112 DOI: 10.1080/10543406.2019.1633654 |
0.463 |
|
| 2019 |
Bayar MA, Ivanova A, Le Teuff G. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method. Computer Methods and Programs in Biomedicine. 176: 211-223. PMID 31200907 DOI: 10.1016/J.Cmpb.2019.04.025 |
0.463 |
|
| 2019 |
Zeidner JF, Vincent BG, Esparza S, Ivanova A, Moore DT, Foster MC, Coombs CC, Jamieson K, Van Deventer HW, Blanchard L, Churchwell W, Frank C, Gallagher S, Matson M, Reed A, et al. Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML Blood. 134: 831-831. DOI: 10.1182/Blood-2019-126065 |
0.306 |
|
| 2019 |
Silverman R, Fine J, Zink RC, Ivanova A. Permutation and Bootstrap Testing for the Sequential Parallel Comparison Design Statistics in Biopharmaceutical Research. 11: 44-51. DOI: 10.1080/19466315.2018.1549095 |
0.379 |
|
| 2019 |
Grover NS, Park SI, Ivanova A, Eldridge P, McKay K, Cheng C, Laing S, Covington D, West J, Sharf E, Morrison JK, Scott S, Crecelius E, Shelley D, Alexander M, et al. A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+ Lymphomas Biology of Blood and Marrow Transplantation. 25: S66. DOI: 10.1016/J.Bbmt.2018.12.149 |
0.309 |
|
| 2018 |
Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Arrowood CC, Reed JE, Garrett-Mead N, Thomas NE, Ollila DW, Ivy SP, ... Ivanova A, et al. NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii453. PMID 32137157 DOI: 10.1093/Annonc/Mdy289.024 |
0.331 |
|
| 2018 |
Davis JM, Ivanova A, Chung Y, Shaw JR, Rao K, Sharf JP, Serody J, Armistead P, Wood WA, Coghill J, Jamieson K, Vincent BG, Riches M, Shea T, Alexander M. Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30244102 DOI: 10.1016/J.Bbmt.2018.09.017 |
0.382 |
|
| 2018 |
Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PD, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. PMID 29964043 DOI: 10.1053/J.Gastro.2018.06.046 |
0.333 |
|
| 2018 |
Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, et al. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. PMID 29905927 DOI: 10.1002/Cncr.31552 |
0.36 |
|
| 2018 |
Grilley-Olson JE, Weiss J, Ivanova A, Villaruz LC, Moore DT, Stinchcombe TE, Lee C, Shan JS, Socinski MA. Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 29631965 DOI: 10.1016/J.Cllc.2018.03.008 |
0.322 |
|
| 2018 |
Silverman RK, Ivanova A, Fine J. Sequential parallel comparison design with binary and time-to-event outcomes. Statistics in Medicine. PMID 29462838 DOI: 10.1002/Sim.7635 |
0.373 |
|
| 2018 |
Zeidner JF, Vincent BG, Ivanova A, Foster MC, Coombs CC, Jamieson K, Van Deventer HW, Blanchard L, Frank C, Gallagher S, Matson M, Pepin K, Vaught L, Vogler N, Miller K, et al. Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML Blood. 132: 4054-4054. DOI: 10.1182/Blood-2018-99-116608 |
0.311 |
|
| 2017 |
Gilman AL, Leung W, Cowan MJ, Cannon M, Epstein S, Barnhart C, Shah K, Hyland M, Fukes T, Ivanova A. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. American Journal of Hematology. PMID 29047161 DOI: 10.1002/Ajh.24949 |
0.333 |
|
| 2017 |
Jia X, Ivanova A, Lee SM. Selection of the initial design for the two-stage continual reassessment method. Journal of Biopharmaceutical Statistics. 1-12. PMID 28300466 DOI: 10.1080/10543406.2017.1290650 |
0.419 |
|
| 2017 |
Parke T, Marchenko O, Anisimov V, Ivanova A, Jennison C, Perevozskaya I, Song G. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result? Journal of Biopharmaceutical Statistics. 1-20. PMID 28281911 DOI: 10.1080/10543406.2017.1289949 |
0.765 |
|
| 2017 |
Chiuzan C, Shtaynberger J, Manji GA, Duong JK, Schwartz GK, Ivanova A, Lee SM. Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Journal of Biopharmaceutical Statistics. PMID 28166468 DOI: 10.1080/10543406.2017.1289952 |
0.372 |
|
| 2017 |
Park SI, Serody JS, Shea TC, Grover NS, Ivanova A, Morrison K, Eldridge P, Mckay K, Cheng CJ, Covington D, Wehner K, Dotti G, Savoldo B. A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma. Journal of Clinical Oncology. 35: TPS3095-TPS3095. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps3095 |
0.313 |
|
| 2017 |
Zeidner JF, Vincent BG, Ivanova A, Foster M, Coombs CC, Jamieson K, Deventer HV, Scibilia R, Blanchard L, Frank C, Gallagher S, Matson M, Pepin K, Vaught L, Vogler N, et al. Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Blood. 130: 1349-1349. DOI: 10.1182/Blood.V130.Suppl_1.1349.1349 |
0.33 |
|
| 2016 |
Ivanova A, Deal AM. Two-stage design for phase II oncology trials with relaxed futility stopping. Statistics and Its Interface. 9: 93-98. PMID 29805727 DOI: 10.4310/Sii.2016.V9.N1.A9 |
0.41 |
|
| 2016 |
Herfarth HH, Jackson S, Schliebe BG, Martin C, Ivanova A, Anton K, Sandler RS, Long MD, Isaacs KL, Osterman MT, Sands BE, Higgins PD, Lewis JD. Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. Inflammatory Bowel Diseases. PMID 27598744 DOI: 10.1097/Mib.0000000000000907 |
0.37 |
|
| 2016 |
Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. British Journal of Haematology. PMID 27448091 DOI: 10.1111/Bjh.14232 |
0.345 |
|
| 2016 |
Ivanova A, Wang Y, Foster MC. The rapid enrollment design for Phase I clinical trials. Statistics in Medicine. PMID 26833922 DOI: 10.1002/Sim.6886 |
0.484 |
|
| 2016 |
Wages NA, Ivanova A, Marchenko O. Practical designs for Phase I combination studies in oncology. Journal of Biopharmaceutical Statistics. 26: 150-66. PMID 26379085 DOI: 10.1080/10543406.2015.1092029 |
0.387 |
|
| 2016 |
O'Neil B, O'Reilly S, Kasbari S, Kim R, McDermott R, Moore D, Grogan W, Cohn A, Bekaii-Saab T, Ivanova A, Olowokure O, Fernando N, McCaffrey J, El-Rayes B, Horgan A, et al. A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy Annals of Oncology. 27: vi153. DOI: 10.1093/Annonc/Mdw370.13 |
0.388 |
|
| 2015 |
Weiss JM, Villaruz LC, O'Brien J, Ivanova A, Lee C, Olson JG, Pollack G, Gorman R, Socinski MA, Stinchombe TE. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clinical Lung Cancer. PMID 26774201 DOI: 10.1016/J.Cllc.2015.12.006 |
0.304 |
|
| 2015 |
McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational New Drugs. 33: 1225-31. PMID 26490655 DOI: 10.1007/S10637-015-0298-3 |
0.442 |
|
| 2015 |
Song G, Ivanova A. Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. Journal of Biopharmaceutical Statistics. 25: 1206-14. PMID 26383917 DOI: 10.1080/10543406.2015.1086779 |
0.783 |
|
| 2015 |
Ivanova A, Zhang Z, Thompson L, Yang Y, Kotz RM, Fang X. Can Sequential Parallel Comparison Design and Two-Way Enriched Design Be Useful in Medical Device Clinical Trials? Journal of Biopharmaceutical Statistics. PMID 26368863 DOI: 10.1080/10543406.2015.1092028 |
0.386 |
|
| 2015 |
Ivanova A, Paul B, Marchenko O, Song G, Patel N, Moschos SJ. Nine-Year Change in Statistical Design, Profile, and Success Rates of Phase II Oncology Trials. Journal of Biopharmaceutical Statistics. PMID 26368744 DOI: 10.1080/10543406.2015.1092030 |
0.777 |
|
| 2015 |
Shea TC, Walko C, Chung Y, Ivanova A, Sheets J, Rao K, Gabriel D, Comeau T, Wood W, Coghill J, Armistead P, Sarantopoulos S, Serody J. Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 2129-35. PMID 26210442 DOI: 10.1016/J.Bbmt.2015.07.016 |
0.432 |
|
| 2015 |
Ivanova A, Hoberman S. Higher order response adaptive urn designs for clinical trials with highly successful treatments. Journal of the Royal Statistical Society. Series C, Applied Statistics. 64: 175-189. PMID 25641991 DOI: 10.1111/Rssc.12066 |
0.394 |
|
| 2015 |
Wang Y, Ivanova A. Dose finding with continuous outcome in phase I oncology trials. Pharmaceutical Statistics. 14: 102-7. PMID 25408518 DOI: 10.1002/Pst.1662 |
0.472 |
|
| 2015 |
Ivanova A, Tamura RN. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Statistical Methods in Medical Research. 24: 871-90. PMID 22143405 DOI: 10.1177/0962280211431023 |
0.396 |
|
| 2015 |
Ivanova A, Song G, Marchenko O, Moschos S. Monitoring rules for toxicity in Phase II oncology trials Clinical Investigation. 5: 373-381. DOI: 10.4155/Cli.15.2 |
0.79 |
|
| 2015 |
Friend R, Xenakis J, Serody JS, Comeau T, Gabriel DA, Sarantopoulos S, Coghill J, Wood WA, Sharf A, Whitley JS, Rao K, Walko CM, Ivanova A, Shea TC, Armistead PM. Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306 Blood. 126: 3117-3117. DOI: 10.1182/Blood.V126.23.3117.3117 |
0.316 |
|
| 2014 |
Weiss JM, Villaruz LC, Socinski MA, Ivanova A, Grilley-Olson J, Dhruva N, Stinchcombe TE. A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer (Amsterdam, Netherlands). 86: 288-90. PMID 25201721 DOI: 10.1016/J.Lungcan.2014.08.011 |
0.307 |
|
| 2014 |
Wang JJ, Ivanova A. Dose finding with the sequential parallel comparison design. Journal of Biopharmaceutical Statistics. 24: 1091-101. PMID 24919070 DOI: 10.1080/10543406.2014.924960 |
0.441 |
|
| 2014 |
McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 74: 117-23. PMID 24819684 DOI: 10.1007/S00280-014-2474-0 |
0.384 |
|
| 2014 |
Farnan L, Ivanova A, Peddada SD. Linear mixed effects models under inequality constraints with applications. Plos One. 9: e84778. PMID 24465432 DOI: 10.1371/Journal.Pone.0084778 |
0.693 |
|
| 2014 |
Bhatnagar S, Hoberman A, Kearney DH, Shaikh N, Moxey-Mims MM, Chesney RW, Carpenter MA, Greenfield SP, Keren R, Mattoo TK, Mathews R, Gravens-Mueller L, Ivanova A. Development and impact of an intervention to boost recruitment in a multicenter pediatric randomized clinical trial. Clinical Pediatrics. 53: 151-7. PMID 24151147 DOI: 10.1177/0009922813506961 |
0.321 |
|
| 2014 |
Stinchcombe TE, Weiss J, Villaruz LC, Ivanova A, Grilley-Olson JE, Dhruva NS, Socinski MA. Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) containing therapy. Journal of Clinical Oncology. 32: e19070-e19070. DOI: 10.1200/Jco.2014.32.15_Suppl.E19070 |
0.323 |
|
| 2013 |
Ivanova A, Xiao C. Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs. Pharmaceutical Statistics. 12: 309-14. PMID 23893900 DOI: 10.1002/Pst.1585 |
0.754 |
|
| 2013 |
Ivanova A, Tamura R. The doubly randomized delayed-start design is the same as the sequential parallel comparison design. Journal of Biopharmaceutical Statistics. 23: 709-10. PMID 23611205 DOI: 10.1080/10543406.2012.738750 |
0.318 |
|
| 2013 |
Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. American Journal of Clinical Oncology. 36: 250-3. PMID 22547007 DOI: 10.1097/Coc.0B013E3182467F22 |
0.398 |
|
| 2013 |
Baer L, Ivanova A. When should the sequential parallel comparison design be used in clinical trials? Clinical Investigation. 3: 823-833. DOI: 10.4155/Cli.13.74 |
0.382 |
|
| 2013 |
Simmons AE, Keisler MD, Ivanova A, Rao KV, Shea TC, Walko CM. Relationship between intravenous (IV) busulfan pharmacokinetics (PK) and patient characteristics in allogeneic stem cell transplant patients. Journal of Clinical Oncology. 31: e13507-e13507. DOI: 10.1200/Jco.2013.31.15_Suppl.E13507 |
0.346 |
|
| 2013 |
Park SI, Richards KL, Asch AS, Olajide O, Deal AM, Ivanova A, Wall JG, Sobol AL, Foster MC, Muss HB, Shea TC. A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma Blood. 122: 1791-1791. DOI: 10.1182/Blood.V122.21.1791.1791 |
0.376 |
|
| 2013 |
Grilley-Olson JE, Villaruz LC, Stinchcombe TE, Weiss J, Shan J, Vashishtha A, Ivanova A, Socinski MA. Abstract B295: A Phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy-naïve incurable stage IIIb/IV non-squamous non-small cell lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B295 |
0.41 |
|
| 2012 |
Ivanova A, Xiao C, Tymofyeyev Y. Two-stage designs for Phase 2 dose-finding trials. Statistics in Medicine. 31: 2872-81. PMID 22865626 DOI: 10.1002/Sim.5365 |
0.761 |
|
| 2012 |
Xiao C, Ivanova A. Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates. Journal of Statistical Planning and Inference. 142: 1899-1907. PMID 22711972 DOI: 10.1016/J.Jspi.2012.01.024 |
0.739 |
|
| 2012 |
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2615-23. PMID 22665533 DOI: 10.1200/Jco.2010.34.5579 |
0.323 |
|
| 2012 |
Foster MC, Amin C, Voorhees PM, van Deventer HW, Richards KL, Ivanova A, Whitman J, Chiu WM, Barr ND, Shea T. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leukemia & Lymphoma. 53: 1331-7. PMID 22149206 DOI: 10.3109/10428194.2011.647313 |
0.404 |
|
| 2012 |
Beaven AW, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, Ford P, Smith J, Goy A. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma. 53: 254-8. PMID 21812533 DOI: 10.3109/10428194.2011.608445 |
0.394 |
|
| 2012 |
Ivanova A, Monaco J, Stinchcombe T. Efficient designs for phase II oncology trials with ordinal outcome Statistics and Its Interface. 5: 463-469. DOI: 10.4310/Sii.2012.V5.N4.A9 |
0.388 |
|
| 2012 |
Foster MC, Kumar P, Walko CM, Ivanova A, Ewesuedo R, Van Deventer H, Garcia R, Park SI, Shea TC. Pharmacokinetic study of clofarabine: Oral bioavailability and the effect of cimetidine on renal clearance. Journal of Clinical Oncology. 30: e13074-e13074. DOI: 10.1200/Jco.2012.30.15_Suppl.E13074 |
0.352 |
|
| 2012 |
Foster MC, Walko C, Kumar P, Huang J, Ivanova A, Garcia R, Deventer HV, Ewesuedo R, Shea TC. Abstract 750: Impairment of clofarabine (CLO) clearance (CL) in the presence of cimetidine: Evidence of a drug-drug interaction between clofarabine and inhibitors of human organic cation transporter-2 (hOCT2) Cancer Research. 72: 750-750. DOI: 10.1158/1538-7445.Am2012-750 |
0.336 |
|
| 2012 |
Grilley-Olson J, Weiss J, Stinchcombe TE, Ivanova A, Tynan M, Shan J, Socinski MA. Abstract 1744: A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naive stage IV non-squamous non-small cell lung cancer Cancer Research. 72: 1744-1744. DOI: 10.1158/1538-7445.Am2012-1744 |
0.418 |
|
| 2012 |
Walko C, Ivanova A, Whitley J, Rao K, Gabriel D, Serody J, Comeau T, Coghill J, Armistead P, Sarantopoulos S, Wood W, Shea T. Beneficial Effect of High-Dose Iv Busulfan (Bu) Delivered by Prolonged Continuous Infusion (CI) on Relapse Rate and Overall Survival (OS) in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies Biology of Blood and Marrow Transplantation. 18: S218. DOI: 10.1016/J.Bbmt.2011.12.044 |
0.33 |
|
| 2011 |
Davies JM, McRee AJ, Sanoff HK, Triglianos T, Keller K, Ivanova A, Bernard SA, Goldberg RM, Dees EC, O'Neil BH. Phase I study of the combination of everolimus (RAD001) with 5FU/LV in patients with refractory solid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 512. PMID 27985743 DOI: 10.1200/Jco.2011.29.4_Suppl.512 |
0.346 |
|
| 2011 |
Ivanova A, Qaqish B, Schoenfeld DA. Optimality, sample size, and power calculations for the sequential parallel comparison design. Statistics in Medicine. 30: 2793-803. PMID 21805484 DOI: 10.1002/Sim.4292 |
0.372 |
|
| 2011 |
Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN, Kim WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer (Amsterdam, Netherlands). 71: 151-5. PMID 20580118 DOI: 10.1016/J.Lungcan.2010.05.022 |
0.344 |
|
| 2011 |
Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B, Stinchcombe TE, Keller K, Dees EC. Phase I trial of vinflunine and pemetrexed in refractory solid tumors. Investigational New Drugs. 29: 131-6. PMID 19830387 DOI: 10.1007/S10637-009-9344-3 |
0.394 |
|
| 2011 |
Shea TC, Walko C, Ivanova A, Whitley J, Rao K, Gabriel DA, Comeau T, Coghill J, Armistead PM, Sarantopoulos S, Wood WA, Serody J. Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies Blood. 118: 1940-1940. DOI: 10.1182/Blood.V118.21.1940.1940 |
0.374 |
|
| 2010 |
Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clinical Breast Cancer. 10: 465-70. PMID 21147690 DOI: 10.3816/Cbc.2010.N.061 |
0.326 |
|
| 2010 |
O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clinical Colorectal Cancer. 9: 119-25. PMID 20378507 DOI: 10.3816/Ccc.2010.N.017 |
0.331 |
|
| 2009 |
Ivanova A, Flournoy N. Comparison of Isotonic Designs for Dose-Finding. Statistics in Biopharmaceutical Research. 1: 101. PMID 20157632 DOI: 10.1198/Sbr.2009.0010 |
0.396 |
|
| 2009 |
Ivanova A, Liu K, Snyder E, Snavely D. An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study. Statistics in Medicine. 28: 2941-51. PMID 19731265 DOI: 10.1002/Sim.3684 |
0.444 |
|
| 2009 |
Ivanova A, Murphy M. An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations. Journal of Biopharmaceutical Statistics. 19: 247-55. PMID 19212877 DOI: 10.1080/10543400802609805 |
0.436 |
|
| 2009 |
Ivanova A, Kim SH. Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach. Biometrics. 65: 307-15. PMID 18479486 DOI: 10.1111/J.1541-0420.2008.01045.X |
0.441 |
|
| 2009 |
Matthew CF, Amin C, Voorhees PM, Van Deventer HW, Richards KL, Ivanova A, Whitman J, Shea TC. A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML). Blood. 114: 2048-2048. DOI: 10.1182/Blood.V114.22.2048.2048 |
0.369 |
|
| 2008 |
Zohar S, Lian Q, Levy V, Cheung K, Ivanova A, Chevret S. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clinical Trials (London, England). 5: 478-85. PMID 18827040 DOI: 10.1177/1740774508096653 |
0.42 |
|
| 2008 |
Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 63: 99-107. PMID 18327587 DOI: 10.1007/S00280-008-0716-8 |
0.324 |
|
| 2008 |
Ivanova A, Bolognese JA, Perevozskaya I. Adaptive dose finding based on t-statistic for dose-response trials. Statistics in Medicine. 27: 1581-92. PMID 18241082 DOI: 10.1002/Sim.3209 |
0.486 |
|
| 2008 |
Salama I, Ivanova A, Qaqish B. Efficient generation of constrained block allocation sequences. Statistics in Medicine. 27: 1421-8. PMID 17729381 DOI: 10.1002/Sim.3014 |
0.315 |
|
| 2008 |
Beaven A, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, Ford P, Smith J, Goy A. A Phase I Study of Bortezomib (Velcade®) Plus 90yttrium Labeled Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 112: 4944-4944. DOI: 10.1182/Blood.V112.11.4944.4944 |
0.373 |
|
| 2008 |
Coghill JM, Nograles KE, Krueger JG, Coghill AS, Serody JS, Ivanova A, Whitley J, Gabriel D, Comeau T, Shea T. Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin Blood. 112: 4350-4350. DOI: 10.1182/Blood.V112.11.4350.4350 |
0.322 |
|
| 2007 |
Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 60: 759-66. PMID 17285317 DOI: 10.1007/S00280-007-0423-X |
0.371 |
|
| 2007 |
Shea T, Serody J, Gabriel D, Comeau T, Ivanova A, Moore D, Irons R, Julia W, Andrew S, Dunphy C, Mark B. Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies. Blood. 110: 4940-4940. DOI: 10.1182/Blood.V110.11.4940.4940 |
0.312 |
|
| 2007 |
Ivanova A, Flournoy N, Chung Y. Cumulative cohort design for dose-finding Journal of Statistical Planning and Inference. 137: 2316-2327. DOI: 10.1016/J.Jspi.2006.07.009 |
0.434 |
|
| 2007 |
Shea T, Walko C, Serody J, Gabriel D, Comeau T, Rao K, Ivanova A, Sharf A, Krasnov C, Coghill A, Whitley J, Lindley C. 273: Safety and efficacy of high-dose busulfan by 90-hour continuous infusion in hematologic malignancy patients undergoing allogeneic stem cell transplants Biology of Blood and Marrow Transplantation. 13: 99-100. DOI: 10.1016/J.Bbmt.2006.12.278 |
0.322 |
|
| 2006 |
Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clinical Breast Cancer. 7: 237-43. PMID 16942640 DOI: 10.3816/Cbc.2006.N.035 |
0.329 |
|
| 2006 |
Ivanova A. Escalation, group and A + B designs for dose-finding trials. Statistics in Medicine. 25: 3668-78. PMID 16381057 DOI: 10.1002/Sim.2470 |
0.429 |
|
| 2006 |
Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 17: 104-9. PMID 16249215 DOI: 10.1093/Annonc/Mdj016 |
0.402 |
|
| 2006 |
Ivanova A, Wang K. Bivariate isotonic design for dose-finding with ordered groups. Statistics in Medicine. 25: 2018-26. PMID 16220476 DOI: 10.1002/Sim.2312 |
0.394 |
|
| 2006 |
Ivanova A, Biswas A, Lurie A. Response-adaptive designs for continuous outcomes Journal of Statistical Planning and Inference. 136: 1845-1852. DOI: 10.1016/J.Jspi.2005.08.008 |
0.356 |
|
| 2005 |
Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 61: 540-5. PMID 16011702 DOI: 10.1111/J.1541-0420.2005.00311.X |
0.454 |
|
| 2005 |
Coad DS, Ivanova A. Sequential urn designs with elimination for comparing K > or =3 treatments. Statistics in Medicine. 24: 1995-2009. PMID 15803441 DOI: 10.1002/Sim.2091 |
0.378 |
|
| 2005 |
Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics. 61: 217-22. PMID 15737096 DOI: 10.1111/J.0006-341X.2005.030540.X |
0.322 |
|
| 2005 |
Ivanova A, Barrier RC, Berger VW. Adjusting for observable selection bias in block randomized trials. Statistics in Medicine. 24: 1537-46. PMID 15723426 DOI: 10.1002/Sim.2058 |
0.36 |
|
| 2005 |
Coad DS, Ivanova A. The use of the triangular test with response-adaptive treatment allocation. Statistics in Medicine. 24: 1483-93. PMID 15706635 DOI: 10.1002/Sim.2051 |
0.334 |
|
| 2005 |
Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 105: 3058-65. PMID 15626743 DOI: 10.1182/Blood-2004-07-2911 |
0.385 |
|
| 2004 |
Ivanova A, Wang K. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Statistics in Medicine. 23: 1861-70. PMID 15195320 DOI: 10.1002/Sim.1796 |
0.448 |
|
| 2004 |
Niell HB, Socinski MA, Bakri K, Wall J, Baggstrom M, Escudero M, Mears A, Tynan M, Ivanova A. Randomized phase II trial comparing every-3-week carboplatin/paclitaxel (C/P) versus every-3-week C with weekly P in advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 7073-7073. DOI: 10.1200/Jco.2004.22.14_Suppl.7073 |
0.374 |
|
| 2004 |
Berger VW, Zhou Y, Ivanova A, Tremmel L. Adjusting for Ordinal Covariates by Inducing a Partial Ordering Biometrical Journal. 46: 48-55. DOI: 10.1002/Bimj.200410012 |
0.331 |
|
| 2003 |
Ivanova A. A new dose-finding design for bivariate outcomes. Biometrics. 59: 1001-7. PMID 14969479 DOI: 10.1111/J.0006-341X.2003.00115.X |
0.315 |
|
| 2003 |
Berger VW, Ivanova A, Knoll MD. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. Statistics in Medicine. 22: 3017-28. PMID 12973784 DOI: 10.1002/Sim.1538 |
0.366 |
|
| 2003 |
Ivanova A, Montazer-Haghighi A, Mohanty SG, Durham SD. Improved up-and-down designs for phase I trials. Statistics in Medicine. 22: 69-82. PMID 12486752 DOI: 10.1002/Sim.1336 |
0.411 |
|
| 2003 |
Socinski MA, Hensing TA, Escudero M, Tynan M, Baggstrom M, Ivanova A, Li J, Bakri K. P-251 Randomized phase II trial of weekly carboplatin/paclitaxel (C/P) versus every-3-week C/P in advanced non-small cell lung cancer (NSCLC): A pure schedule trial Lung Cancer. 41: S155-S156. DOI: 10.1016/S0169-5002(03)92220-3 |
0.345 |
|
| 2003 |
Ivanova A. A play-the-winner-type urn design with reduced variability Metrika. 58: 1-13. DOI: 10.1007/S001840200220 |
0.354 |
|
| 2001 |
Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML. Optimal adaptive designs for binary response trials Biometrics. 57: 909-913. PMID 11550944 DOI: 10.1111/J.0006-341X.2001.00909.X |
0.62 |
|
| 2001 |
Ivanova A, Rosenberger WF. Adaptive designs for clinical trials with highly successful treatments Drug Information Journal. 35: 1087-1093. DOI: 10.1177/009286150103500406 |
0.639 |
|
| 2001 |
Coad DS, Ivanova A. BIAS CALCULATIONS FOR ADAPTIVE URN DESIGNS Sequential Analysis. 20: 91-116. DOI: 10.1081/Sqa-100106051 |
0.369 |
|
| Show low-probability matches. |